MedTrace Logo

A Trial of Antroquinonol in Patients With Atopic Dermatitis

NCT03622463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-08-29

No results posted yet for this study

Summary

This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis.Duration of treatment is 12 week in total. Study visits will occur every 4 weeks. AEs/SAEs, changes to concomitant medications will be noted, vital signs will be taken, and efficacy evaluations will be performed as well. The last estimation of variable scores will occur for all subjects.

Conditions

Interventions

DRUG

Antroquinonol

Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.

OTHER

Placebo

The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    lead INDUSTRY

Principal Investigators

  • Cheng-Chung Wei, MD · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-17
Primary Completion
2019-07-09
Completion
2019-07-09

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03622463 on ClinicalTrials.gov